Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · September 23, 2022

BLOOD 2022: Axi-Cel Superior to Standard of Care as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma

Researchers say axi-cel should replace chemoimmunotherapy as second-line standard of care for early relapsed/refractory LBCL

PracticeUpdate Editorial Team


Further Reading